Fig. 6
From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
Targeting CA916798 enhances Gefitinib inhibitory effects on LUAD cells
A) Flow chart of in vivo experiment. CMC-Na is used as control for Gefitinib
B-D) Tumor image (B), tumor volume (C), and tumor weight (D) of xenograft models generated using PC9/GR cells stably transfected with control shRNA (Mock) or shCA916798 treated with CMC-Na or Gefitinib. Data are shown as mean ± SD (n = 5, *P < 0.05, ***P < 0.001
E) Representative HE staining of xenograft tumors. Scale bar = 100 μm (upper panels) or 25 μm (lower panels)